LH
HealthcareLabcorp Holdings Inc. · Medical - Diagnostics & Research · $21B
What is Labcorp Holdings Inc.?
Labcorp is a large-cap healthcare company that delivers laboratory testing and diagnostics services to clinicians, hospitals, pharmaceutical companies, and patients across the United States and beyond.
Labcorp generates revenue by processing clinical lab tests ordered by physicians and health systems, and by providing drug development support services to pharmaceutical and biotech clients. Its two-sided model spans routine diagnostics for everyday patient care and specialized testing that supports clinical trials and research programs.
Founded in 1990 and headquartered in Burlington, North Carolina.
- Clinical laboratory testing and diagnostics
- Drug development and clinical trial support
- Specialty and genomic testing services
Is LH a Good Stock to Buy?
UQS Score rates LH as Below Average overall.
Valuation stands out as the most favorable pillar, suggesting the stock is not richly priced relative to its fundamentals. Quality, Moat, and Growth all register as Neutral, reflecting a stable but undifferentiated competitive position.
The Risk pillar is rated Weak, which is the primary drag on the overall score and warrants careful attention.
Sign up to see the exact pillar breakdown and the full financial metrics behind each rating. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LH pay dividends?
Yes — Labcorp Holdings Inc. pays a dividend.
Labcorp pays a regular dividend, which may appeal to income-oriented investors. A company of this scale in the healthcare services sector often returns capital to shareholders while maintaining operational investment. Check Labcorp's investor relations page for the current yield and payment schedule.
When does LH report earnings?
Labcorp reports earnings on a quarterly cadence, typical for US-listed large-cap equities.
Results have reflected the broader normalization of testing volumes following the pandemic-era surge, with the company balancing its core diagnostics business against ongoing investment in drug development services. Revenue trends across both segments influence how the market interprets each quarterly update.
For the most recent quarter's results, visit Labcorp's investor relations page directly.
LH Price History
+21.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Labcorp Holdings Inc.?
Based on Labcorp Holdings Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Labcorp do?
Labcorp provides laboratory testing services to doctors, hospitals, patients, and pharmaceutical companies. Its work spans routine clinical diagnostics and specialized testing that supports drug development and clinical research programs.
Does LH pay dividends?
Yes, Labcorp pays a regular dividend. Income-focused investors should check the company's investor relations page for the current dividend rate and payment schedule, as these details can change.
When does LH report earnings?
Labcorp follows a standard quarterly earnings cadence. For the exact date of the next scheduled report, refer to the investor relations section of Labcorp's official website.
Is LH a good stock to buy?
UQS Score rates LH as Below Average, driven largely by a Weak Risk pillar. Valuation is rated Good, which provides some offset. Investors should weigh the favorable valuation against the elevated risk profile before making any decision.
Is LH overvalued?
Based on the UQS Valuation pillar, LH is rated Good, suggesting the stock is not considered overvalued relative to its fundamentals. That said, valuation alone does not determine overall quality — the full picture includes risk and growth dynamics.
What is LH's market cap bracket?
Labcorp is classified as a large-cap company, placing it among the more established and widely followed names in the healthcare services sector.
Is LH a long-term quality investment?
As a long-term quality indicator, LH's Below Average UQS Score reflects Neutral readings across Quality, Moat, and Growth, alongside a Weak Risk rating. Long-term investors may want to monitor how the risk profile evolves before committing capital.
What sector does LH belong to?
Labcorp operates in the Healthcare sector, specifically within laboratory and diagnostics services. It serves both the clinical care market and the pharmaceutical research and development market.
Unlock Full LH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access the complete financial metrics behind each rating
- ✓Compare LH against sector peers on a standardized scoring framework
- ✓Get the full analyst-grade breakdown available to Pro members
Pro Analysis
LH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 48.3 | 46.0 | 42.0 | 45.5 | 35.3 | 79.1 | +5.6 |
| May 10, 2026 | 42.7 | 12.1 | 42.0 | 45.4 | 46.4 | 87.3 | +0.1 |
| May 8, 2026 | 42.6 | 12.1 | 42.0 | 45.4 | 46.4 | 86.7 | -4.5 |
| May 7, 2026 | 47.1 | 42.5 | 42.0 | 45.4 | 31.9 | 80.5 | -0.1 |
| May 4, 2026 | 47.2 | 42.5 | 42.0 | 45.4 | 31.9 | 81.4 | 0.0 |
| May 3, 2026 | 47.2 | 42.5 | 42.0 | 45.3 | 31.9 | 81.3 | +0.2 |
| Apr 26, 2026 | 47.0 | 42.5 | 42.0 | 45.3 | 31.9 | 80.3 | +0.2 |
| Apr 19, 2026 | 46.8 | 42.5 | 42.0 | 45.3 | 31.9 | 78.7 | -0.4 |
| Apr 18, 2026 | 47.2 | 42.9 | 42.0 | 45.3 | 31.9 | 80.9 | -0.6 |
| Apr 14, 2026 | 47.8 | 42.9 | 42.0 | 45.3 | 31.9 | 84.9 | -0.1 |
LH — Pillar Breakdown
Quality
— 46.0/100 (25%)Labcorp Holdings Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 45.5/100 (20%)Labcorp Holdings Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 35.3/100 (15%)Labcorp Holdings Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 77.9/100 (15%)Labcorp Holdings Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Labcorp Holdings Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LH.
Score Composition
Financial Data
More Stock Analysis
How is the LH UQS Score Calculated?
The UQS (Unified Quality Score) for Labcorp Holdings Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Labcorp Holdings Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Labcorp Holdings Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.